(Yicai Global) July 30 -- Shares of Da An Gene surged to a historic high after the Chinese genomic sequencing firm said that its net profit had risen by more than 11 times in the first half of this year from a year ago due to the strong demand for its Covid-19 testing kits.

The medical company's stock price [SHE: 002030] jumped by the daily limit of 10 percent to CNY40.83 (USD5.80) today. The equity price has more than tripled this year.

Da An Gene's net profit rose to CNY762 million (USD108.8 million) over the six months on surging demand, the Guangzhou-based firm said in a statement this morning. Meanwhile, its revenue jumped fourfold to CNY2.1 billion (USD299.8 million).

The company didn't reveal predictions of its future performance.

Editor: Emmi Laine